SOURCE: SK3 Group, Inc.

March 10, 2010 09:00 ET

SK3 Group's Parent Company Signs Letter of Intent for Medical Product Developer

MIAMI, FL--(Marketwire - March 10, 2010) -  SK3 Group, Inc.'s (PINKSHEETS: SKTO) parent company, Healthcare of Today, Inc. (, has announced the signing of a letter of intent with leading edge medical product company DyfucaMed®, LLC ("DyfucaMed®").

DyfucaMed®'s flagship product is the DyfucaMed® Ratio Applicator, a medical biomaterials applicator for performing Autogenous Hematopoetic Tissue Grafts ("AHTG"). Using stem cell technology and controlled application of a concentrated platelet gel, the DyfucaMed® Ratio Applicator allows the body to use its own healing mechanisms for therapeutic benefits and accelerated healing. Platelet Gel has received attention as the medical choice for athletes who require a rapid recovery, including NFL player Hines Ward. The use of a platelet gel applicator is appealing for a number of markets requiring aggressive recovery, including the military and veterinary markets. 

DyfucaMed® creates user-driven medical solutions, consulting with medical professionals who regularly use tissue grafts to gain insight into market needs during various stages of product development. In one example, the DyfucaMed® Ratio Applicator uses a plastic polycarbonate that is the first disposable applicator to be lipid-resistant and has finger grips to prevent slippage. 

The development of the DyfucaMed® Ratio Applicator was inspired by surgeons' increasing recommendation of the use of platelet gel. Platelet gel offers a number of benefits including accelerated tissue regeneration, helping create hemostasis, reducing pain, helping prevent infection, and reducing the chance of adhesions. Clinical uses of autologous platelet gel are numerous and include plastic surgery, orthopedic surgery including hip replacements, neurosurgery, major vascular surgery, cardio-thoracic surgery, oral surgery, and chronic wounds such as diabetic foot ulcers. 

CEO of DyfucaMed® Lawrence Williams says, "The DyfucaMed® Ratio Applicator improves healing time and prevents bruising. Platelet gel can often make a dramatic difference, such as the difference between a patient having a limb amputated or healing the sore and moving on. We are thrilled to bring our products into the Healthcare of Today family of businesses and we share its passion for finding new and innovative ways to improve patient outcomes."

Healthcare of Today VP of International Business Development Daniel McKeown says, "DyfucaMed® has taken the time to understand what doctors say they need to help their patients heal faster, and has developed those tools. We are thrilled to bring their cutting-edge line of products on board with Healthcare of Today and to vertically integrate them into our family of companies so our patients and businesses across the board can benefit from their ground-breaking product line. We look forward to working with DyfucaMed® to find new ways to restore our patients, young and old, to their best health."

About Healthcare of Today, Inc.

Healthcare of Today, Inc. (, formed in 2008, acquires and develops companies primarily within the healthcare industry. Through its many subsidiaries, Healthcare of Today owns and operates a number of vertically integrated businesses including: adult stem cell research and development technology, advanced human tissue engineering, medical device technology, medical and home healthcare equipment sales, hospice care, residential care facilities for the elderly, home healthcare services, nurse and therapist staffing, healthcare information technology, healthcare consulting, insurance, medical billing, data protection and security. For more information please visit

About SK3 Group, Inc.
SK3 Group markets preferred medical services through its facilitation partners to its PEO client base. Corporate information can be found at

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:
    SK3 Group, Inc.
    Peter Bell
    Tel: (760) 268-9611
    Email Contact